TORCH: Tranexamic Acid to Prevent Operation in Chronic Subdural Hematoma

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514927-40-02

Enrollment

554

Registered

2024-09-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Subdural Hematoma

Brief summary

Need to undergo surgery for chronic subdural hematoma within 12 weeks after TXA treatment initiation less often compared to those receiving a placebo

Interventions

DRUGThe placebo capsules are not over-encapsulated

DRUGand only contain a mixture of cellulose and magnesium.

DRUGTRANEXAMIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Need to undergo surgery for chronic subdural hematoma within 12 weeks after TXA treatment initiation less often compared to those receiving a placebo	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026